SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ADVENTRX Pharmaceuticals Inc (Anx)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Steve Lokness who wrote (323)10/2/2007 12:19:59 PM
From: Keith FeralRead Replies (1) of 418
 
I don't really see your point about charts being a form of due diligence for biotechs. Biotechs have to pass the burden of statistical significance, at least that is the case for Cofactor.

Fortunately, the rest of the drugs are being groomed for bioequivalency trials - 505b2. 28 patient studies with the same pk pathway for vinorelbine and docetaxel. It will be interesting to see the phase 3 data for vinorelbine next month.

Maybe the charts will show a buy signal from the $0.50 washout.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News